JP2023526980A - ハードカプセル剤形及びその使用 - Google Patents

ハードカプセル剤形及びその使用 Download PDF

Info

Publication number
JP2023526980A
JP2023526980A JP2022571817A JP2022571817A JP2023526980A JP 2023526980 A JP2023526980 A JP 2023526980A JP 2022571817 A JP2022571817 A JP 2022571817A JP 2022571817 A JP2022571817 A JP 2022571817A JP 2023526980 A JP2023526980 A JP 2023526980A
Authority
JP
Japan
Prior art keywords
hydroxyvitamin
dosage form
hard capsule
optionally
calcifediol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526980A5 (https=
Inventor
リーム エラメイン エルシディグ
コルム ナルティ
Original Assignee
エアジェン ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000220 external-priority patent/WO2021205225A1/en
Application filed by エアジェン ファーマ リミテッド filed Critical エアジェン ファーマ リミテッド
Publication of JP2023526980A publication Critical patent/JP2023526980A/ja
Publication of JP2023526980A5 publication Critical patent/JP2023526980A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022571817A 2020-05-31 2021-05-31 ハードカプセル剤形及びその使用 Pending JP2023526980A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection
IBPCT/IB2021/000220 2021-04-06
PCT/IB2021/000376 WO2021245458A1 (en) 2020-05-31 2021-05-31 Hard capsule dosage form and uses thereof

Publications (2)

Publication Number Publication Date
JP2023526980A true JP2023526980A (ja) 2023-06-26
JP2023526980A5 JP2023526980A5 (https=) 2024-06-06

Family

ID=78831505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571817A Pending JP2023526980A (ja) 2020-05-31 2021-05-31 ハードカプセル剤形及びその使用

Country Status (9)

Country Link
US (2) US20230293552A1 (https=)
EP (1) EP4157231A1 (https=)
JP (1) JP2023526980A (https=)
KR (1) KR20230017192A (https=)
CN (2) CN120694962A (https=)
AU (1) AU2021285494A1 (https=)
CA (1) CA3181945A1 (https=)
IL (1) IL297885A (https=)
WO (1) WO2021245458A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
CN119907688A (zh) * 2022-09-20 2025-04-29 比利时胶囊公司 含有氧化镁的遮光硬胶囊
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505928A (ja) * 2009-09-24 2013-02-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 耐酸性カプセル
JP2016502562A (ja) * 2012-12-05 2016-01-28 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 硬質カプセル
JP2018534254A (ja) * 2015-09-25 2018-11-22 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP2023520591A (ja) * 2020-04-06 2023-05-17 エアジェン ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) * 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
CN101595133B (zh) * 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) * 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
EP2321273B1 (en) * 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
BR112020000011A2 (pt) * 2017-07-11 2020-07-21 Qualicaps Co., Ltd. cápsula dura entérica
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505928A (ja) * 2009-09-24 2013-02-21 キャプシュゲル・ベルジウム・エヌ・ヴィ 耐酸性カプセル
JP2016502562A (ja) * 2012-12-05 2016-01-28 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 硬質カプセル
JP2018534254A (ja) * 2015-09-25 2018-11-22 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法及びそのための物品
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP2023520591A (ja) * 2020-04-06 2023-05-17 エアジェン ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ

Also Published As

Publication number Publication date
CN115768412A (zh) 2023-03-07
WO2021245458A1 (en) 2021-12-09
CN120694962A (zh) 2025-09-26
EP4157231A1 (en) 2023-04-05
KR20230017192A (ko) 2023-02-03
US20230293552A1 (en) 2023-09-21
AU2021285494A1 (en) 2022-12-08
US20230330110A1 (en) 2023-10-19
CA3181945A1 (en) 2021-12-09
IL297885A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
JP7282832B2 (ja) 安定化調整放出ビタミンｄ製剤及びその投与方法
US20230330110A1 (en) Hard capsule dosage form and uses thereof
AU2021107168A4 (en) Vitamin d pediatric dosage forms, methods of making and using
TWI645864B (zh) 經穩定之修飾釋放維他命ｄ調配物及其服用方法
TWI812891B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
TWI743426B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
HK40033528A (en) Stabilized modified release vitamin d formulation and method of administering same
NZ711924B2 (en) Stabilized modified release vitamin d formulation and method of administering same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401